Back to today’s briefing

Story perspectives

Exagen Reports Strong Q2 Growth Amid Rising Losses

7/30/2025

50 5

Summary

Story summary

Exagen, a diagnostics leader, celebrated a strong Q2 2025 with revenue hitting $17.2 million, surpassing forecasts by 5.5% and marking a 14.2% year-over-year growth. Despite this success, the net loss grew to $4.4 million amid rising operating costs. Looking ahead, Exagen targets $65-$70 million in revenue, emphasizing the adoption of its AVISE CTD test.

1 of 1

Story summary

Exagen, a diagnostics leader, celebrated a strong Q2 2025 with revenue hitting $17.2 million, surpassing forecasts by 5.5% and marking a 14.2% year-over-year growth. Despite this success, the net loss grew to $4.4 million amid rising operating costs. Looking ahead, Exagen targets $65-$70 million in revenue, emphasizing the adoption of its AVISE CTD test.